MIAMI--(BUSINESS WIRE)--April 14, 2005--DOR BioPharma, Inc. (AMEX:DOR); (“DOR”, or the “Company”) today announced that Gregory Davenport, Ph.D., President of DOR’s BioDefense Division, will participate as a panelist during the Bio-Chem Defense Vaccine and Therapeutics Conference from April 18 - 20, 2005, at the Hilton Arlington & Towers in Arlington, Virginia. The panel’s title is “The Business Case for Developing and Producing Bio-Chem Defense Vaccines and Therapeutics - Understanding Project Bioshield.” The panel will consist of prominent members of the biotech industry as well as a representative from the U.S. Department of Health and Human Services. The panel will discuss the requisite conditions necessary to support a business model that will secure the industry’s commitment to BioDefense, and as well as integral conditions to winning procurement contracts. The panel discussion will take place on Tuesday, April 19 at 4:00 PM. For the complete conference agenda, please visit the conference website at http://www.infocastinc.com/biovac.html.
